Salix Pharmaceuticals is a specialty pharmaceutical company committed to offering innovative treatments in gastroenterology, endocrinology, and other conditions.

It is our mission to provide the most effective solutions to healthcare professionals and patients

We license, develop, and market products such as XIFAXAN® (rifaximin) 550 mg, RUCONEST® (C1 esterase inhibitor [recombinant]), RELISTOR® (methylnaltrexone bromide) tablets, RELISTOR® (methylnaltrexone bromide) subcutaneous injection, APRISO® (mesalamine), GIAZO® (balsalazide disodium), MOVIPREP® (PEG-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid for oral solution), OSMOPREP® (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP), SOLESTA®, DEFLUX®, UCERIS® (budesonide) extended release tablets, UCERIS® (budesonide) rectal foam, GLUMETZA® (metformin), CYCLOSET® (bromocriptine mesylate) and ZEGERID® (omeprazole/sodium bicarbonate).